Description and references

Glycopeptide antibiotic complex produced by Actinoplanes teichomyceticus nov. sp.; structurally related to vancomycin, q.v. Comprised of 5 major components differentiated by a specific fatty acid moiety. Inhibits peptidoglycan synthesis in the cell wall of gram-positive bacteria. Isoln: BE 839259; C. Coronelli et al., US 4239751 (1976, 1980 both to Lepetit); F. Parenti et al., J. Antibiot. 31, 276 (1978); M. R. Bardone et al., ibid. 170. Separation of components: A. Borghi et al., DE 3320342; eidem, US 4542018 (1983, 1985 both to Lepetit); eidem, J. Antibiot. 37, 615 (1984). Structural studies: C. Coronelli et al., ibid. 621; J. C. J. Barna et al., J. Am. Chem. Soc. 106, 4895 (1984). Comparative in vitro activity: M. H. Cynamon, P. A. Granato, Antimicrob. Agents Chemother. 21, 504 (1982); H. C. Neu, P. Labthavikul, idem, 24, 425 (1983). Human pharmacokinetics: L. Verbist et al., ibid. 26, 881 (1984); P. L. Carver et al., ibid. 33, 82 (1989). Mechanism of action: S. Somma et al., ibid. 26, 917 (1984). Synergism with rifampin, q.v.: C. Watanakunakorn, J. Antimicrob. Chemother. 19, 439 (1987). HPLC determn in human serum: J. Levy et al., ibid. 533. Clinical trial in gram-positive bacterial infections: Y. Glupczynski et al., Antimicrob. Agents Chemother. 29, 52 (1986). Brief review: A. H. Williams, R. N. Grüneberg, J. Antimicrob. Chemother. 14, 441 (1984). Symposium on chemistry, pharmacology, activity, and clinical trials: J. Hosp. Infect. 7, Suppl. A, 47-112 (1986).

Properties

Derivative

Derivative

Derivative

Derivative

Derivative